Cervical cancer is one of the most common malignant tumors that seriously threatens women’s health and ranks first among malignant tumors of women in China. Patients with early stage of cervical cancer can choose surgery or radiotherapy to get radical cure, while patients with middle and late stage can be treated with simultaneous radiotherapy, i.e. traditional total external pelvic irradiation + intracavitary rear-loading irradiation + concurrent chemotherapy, which has a better prognosis. However, once recurrence occurs, surgery is generally not possible and chemotherapy alone is not effective. If conventional radiotherapy is received, the dose of tumor treatment has to be reduced in order to avoid the appearance of serious radiation side effects in the surrounding tissues irradiated in the anterior and posterior pelvic fields, so that the dose is difficult to reach an effective lethal amount. In particular, patients who have been treated with radiotherapy before are not rich in blood supply due to fibrosis of pelvic tissues after initial radiotherapy, and the tumor central hypoxic cells are not sensitive to radiotherapy, resulting in reduced radiosensitivity during re-radiotherapy. The local control rate of tumor is mainly related to the radiation dose of the tumor, and increasing the radiation dose is the best way to control the tumor. The limitation of the dose tolerated by adjacent tissues and organs restricts the dose of radiation therapy to the lesion and affects the treatment effect. The clinical application of 3D-CRT and IMRT is widely concerned because they have the characteristics of increasing the local dose and reducing the damage of normal tumor surrounding tissues, and can achieve the ideal dose distribution through precise body fixation and precise radiotherapy plan design. In 3D-CRT and IMRT planning, the most important thing is the determination and outline of the target area, and the concepts of the Gross Tumor Volume (GTV), the Clinical Target Volume (CTV) and the Planning Target Volume (PTV) should be clarified. In recent years, our department has adopted 3D-CRT and IMRT technology in combination with chemotherapy to treat recurrent cervical cancer with good results. The target area is outlined by a gynecologic oncologist in collaboration with a physiatrist after the patient’s CT simulation and clinical gynecologic triage examination. It makes the dose distribution of radiotherapy treatment for recurrent cervical cancer more reasonable, minimizes the exposure and irradiation volume of adjacent normal groups such as rectum, small intestine, bladder and spinal cord, and increases the treatment dose of tumor while reducing the side effects of radiation therapy. It significantly relieves patients’ symptoms, alleviates patients’ pain, reduces patients’ side effects and improves patients’ survival rate. It brings new hope to patients with recurrent cervical cancer.